Baipharm
ChemLinkedMarketChemicalFoodCosmeticBaiPharm Agrochemical Japan
News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
INDUSTRY
Marketing Approval Innovative Drug Generic Drug Biological Product Cancer Vaccine Drug Registration New Drug
Monthly Report: New Drug Approvals in China | February 2023 In Feb. 2023, China NMPA approved 13 new drugs, including 9 chemical drugs and 4 biological products. 1. Carephar’s Keverprazan Hydrochloride Tablets 2. Novartis’ Revolade 3. Pfizer’s Xeljanz XR 4. Vifor Fresenius’ Velphoro 5. Swedish Orphan Biovitrum’s Orfadin (capsule) 6. Swedish Orphan Biovitrum’s Orfadin (oral suspension) 7. Gilead Sciences’ AmBisome 8. AbbVie’s RINVOQ 9. Tide Pharma’s Limaprost Alfadex Tablets 10. BeiGene’s Tislelizumab Injection 11. Daiichi-Sankyo’s ENHERTU 12. Amgen’s Prolia 13. Sanofi Pasteur’s Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Mar 03, 2023
INDUSTRY
Marketing Approval Priority Review and Approval Innovative Drug Generic Drug Biological Product Cancer Drug Registration New Drug COVID-19
Monthly Report: New Drug Approvals in China | January 2023 In January 2023, China NMPA approved 15 new drugs, including 8 chemical drugs and 7 biological products. Simcere's Simnotrelvir Tablets / Ritonavir Tablets and Shanghai Vinnerna Biosciences' Deuremidevir Hydrobromide got conditional approvals for COVID-19 treatment.
Feb 03, 2023
INDUSTRY
Marketing Approval Generic Drug Biological Product Drug Registration New Drug COVID-19
Monthly Report: New Drug Approvals in China | December 2022 In December 2022, China NMPA approved 7 new drugs, including 6 chemical drugs and 1 biological product.
Jan 06, 2023
INDUSTRY
Marketing Approval Innovative Drug Drug Registration New Drug COVID-19
[Updated] China Conditionally Approves MSD's Molnupiravir for COVID-19 Treatment On Dec. 29, 2022, China NMPA conditionally approved Merck Sharp & Dohme (MSD)’s Molnupiravir Capsules (brand name: Lagevrio) for COVID-19 treatment.
Jan 05, 2023
INDUSTRY
E-commerce
China O2O Retail Pharmacy Market Analysis: Sales, Popular Platforms, Best-selling Products, and More In 2021, O2O retail pharmacies in China realized a total revenue of 20.2 billion yuan (circa 2.89 billion USD), accounting for 3.5% of the Chinese pharmacy market.
Jan 03, 2023
INDUSTRY
Marketing Approval Innovative Drug Generic Drug Biological Product Cancer Cardiovascular Disease Vaccine Drug Registration New Drug
Monthly Report: New Drug Approvals in China | November 2022 In October 2022, China NMPA approved 14 new drugs, including 12 chemical drugs and 2 biological products.
Dec 05, 2022
INDUSTRY
Innovative Drug Cancer Cell Therapy Gene Therapy
China Pharma Industry Sees More M&A Deals In 2021, Chinese pharma companies participated in a total of 782 domestic and cross-border M&A deals, amounting to 34,436 million USD.
Dec 02, 2022
INDUSTRY
Clinical Trial Cancer New Drug
Bispecific Antibody Becomes a Hotspot for Pharmaceutical Research in China In China, over 300 bispecific antibody (BsAb) drugs are being developed, among which nearly 100 have entered the clinical trial stage. By 2030, the Chinese BsAb market is expected to reach 10.8 billion USD.
Nov 25, 2022
INDUSTRY
Clinical Trial
Top 10 CROs Using China's Human Genetic Resources in International Clinical Trials From Jan. to Oct. 2022, among the 3,632 international clinical trials approved by China to use the its human genetic resources outside China, about 52% are conducted by contract research organizations (CROs) and about 48% by the applicants themselves.
Nov 23, 2022
INDUSTRY
Marketing Approval Priority Review and Approval Innovative Drug Cancer Diabetes Drug Registration New Drug
Monthly Report: New Drug Approvals in China | October 2022 In October 2022, China NMPA approved 17 new drugs, including 11 chemical drugs and 6 biological products.
Nov 03, 2022
12345 ...6 Next
Most Popular